Carfilzomib: all 165 studies that test it
Page 2 of 2. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.
- Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMActive, not recruitingNCT04176718Phase 2
- Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT04163107Phase 1
- A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for TransplantActive, not recruitingNCT04096066Phase 3
- Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM PatientsCompletedNCT04065789Phase 2
- Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCLStatus unknownNCT03891355Phase 2
- Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and DesensitizationWithdrawnNCT03805178Phase 2
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT03798678Phase 1
- Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)Status unknownNCT03795597Phase 1/2
- Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple MyelomaActive, not recruitingNCT03756896Phase 2
- Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsActive, not recruitingNCT03742297Phase 3
- Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)Active, not recruitingNCT03729804Phase 3
- Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMMActive, not recruitingNCT03673826Phase 2
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
- An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsActive, not recruitingNCT03606577Phase 2
- A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell TransplantationActive, not recruitingNCT03556332Phase 2
- Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaActive, not recruitingNCT03500445Phase 2
- Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.Active, not recruitingNCT03314636Phase 2
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantActive, not recruitingNCT03289299Phase 2
- Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma PatientsCompletedNCT03141203Phase 1/2
- Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT03140943Phase 2
- Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and DexamethasoneActive, not recruitingNCT03104842Phase 2
- Combination Study for High Risk Multiple Myeloma PatientsTerminatedNCT03104270Phase 2
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)Active, not recruitingNCT02899052Phase 2
- Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatWithdrawnNCT02802163Phase 1/2
- Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple MyelomaActive, not recruitingNCT02659293Phase 3
- Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell SupportStatus unknownNCT02572492Phase 2
- Carfilzomib in Combination With Cyclophosphamide and Etoposide for ChildrenCompletedNCT02512926Phase 1
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT02332850Phase 1
- Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple MyelomaCompletedNCT02302495Phase 2
- Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or LymphomaCompletedNCT02293109Phase 1
- Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell LymphomaTerminatedNCT02269085Phase 1
- Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid TumorsCompletedNCT02257476Phase 1
- Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple MyelomaCompletedNCT02217163Phase 2
- Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02204241Phase 1/2
- Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02199665Phase 1
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)CompletedNCT02185820Phase 1/2
- Carfilzomib Plus Belinostat in Relapsed/Refractory NHLCompletedNCT02142530Phase 1
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
- Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02101944Phase 1
- Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02095834Phase 1
- Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple MyelomaCompletedNCT02056756Phase 1/2
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedNCT01998971Phase 1
- Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01926665Phase 1
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT01863550Phase 3
- Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)CompletedNCT01857115Phase 1/2
- Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell TransplantWithdrawnNCT01812720Phase 2
- Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple MyelomaStatus unknownNCT01792102Phase 1/2
- A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain AmyloidosisCompletedNCT01789242Phase 1
- Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01729104Phase 1
- A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed MyelomaCompletedNCT01660750Phase 1
- Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple MyelomaCompletedNCT01549431Phase 1
- Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple MyelomaTerminatedNCT01537861Early Phase 1
- A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01464034Phase 1/2
- Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT01372540Phase 1
- Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma PatientsCompletedNCT01346787Phase 2
- Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01336920Phase 1
- Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01301807Phase 1
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT01297764Phase 1/2
- Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)CompletedNCT01279694Phase 1/2
- Study of Carfilzomib and Vorinostat for Relapsed or Refractory LymphomaCompletedNCT01276717Phase 1
- Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)CompletedNCT01212380Phase 1
- Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic LeukemiaCompletedNCT01137747Phase 1